ストックスクリーナーアプリを入手
4.01
0.25%
-0.010
アフターアワーズ：
4.00
-0.010
-0.25%
前日終値:
$4.02
開ける：
$4.07
24時間の取引高:
125.99K
Relative Volume:
1.64
時価総額：
$37.10M
収益：
$6.16M
当期純損益:
$-25.59M
株価収益率:
-1.385
EPS:
-2.8954
ネットキャッシュフロー:
$-24.93M
1週間 パフォーマンス:
-8.86%
1か月 パフォーマンス:
-12.83%
6か月 パフォーマンス:
-61.85%
1年 パフォーマンス:
+85.65%
1日の値動き範囲:
$3.76
$4.08
1週間の範囲:
$3.58
$4.4499
52週間の値動き範囲:
$1.92
$16.94
Cervomed Inc Stock (CRVO) Company Profile
Compare CRVO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
4.01 | 37.20M | 6.16M | -25.59M | -24.93M | -2.8954 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-13 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-12-05 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-18 | 開始されました | Chardan Capital Markets | Buy |
| 2024-07-26 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-15 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cervomed Inc (CRVO) 最新ニュース
Chardan Capital Maintains Buy Rating for CRVO | CRVO Stock News - GuruFocus
CervoMed to Participate in Upcoming Investor Conferences - The Manila Times
Biotech chasing age-related brain drugs makes March investor pitch - Stock Titan
CervoMed sets 50mg dose for phase 3 dementia trial By Investing.com - Investing.com Canada
CervoMed Finalizes Formulation and Dosing Regimen for Phase 3 Trial in Dementia with Lewy Bodies - geneonline.com
CervoMed sets 50mg dose for phase 3 dementia trial - Investing.com Australia
CervoMed Advances Neflamapimod With Phase 1 Completion - TipRanks
CervoMed (CRVO) Analyst Rating Update: Buy Rating Maintained by D. Boral Capital | CRVO Stock News - GuruFocus
Phase 3 neflamapimod dose set at 50 mg, CervoMed Inc. asserts - Traders Union
CervoMed Inc. Announces Successful Phase 1 Study of Stable Crystal Form of Neflamapimod and Planned Phase 3 Trial Dosing Regimen for Dementia with Lewy Bodies - Quiver Quantitative
CervoMed picks 50mg dose for dementia drug after Phase 1 study - Stock Titan
Can CervoMed Inc reach all time highs this year2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Guidance Update: Can CervoMed Inc reach all time highs this year2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
How do insiders feel about CervoMed Inc2025 Institutional Moves & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Stock Analysis: What is CervoMed Incs revenue forecastJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - baoquankhu1.vn
CRVOCervoMed Latest Stock News & Market Updates - Stock Titan
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target - TipRanks
CervoMed’s neflamapimod selected for UK ALS trial platform By Investing.com - Investing.com Canada
CervoMed’s Neflamapimod Added to U.K. ALS Platform - TipRanks
CervoMed's neflamapimod selected for UK EXPERTS-ALS; first ALS dosing expected by end of 2026 - TradingView
Neflamapimod joins UK EXPERTS-ALS platform for ALS at CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed (CRVO) Analyst Rating Maintained as "Buy" by D. Boral C - GuruFocus
CervoMed’s neflamapimod selected for UK ALS trial platform - Investing.com
CervoMed's Neflamapimod Chosen For UK EXPERTS-ALS Platform - Nasdaq
CervoMed (CRVO) Drug Candidate Joins EXPERTS-ALS Platform - GuruFocus
CervoMed's neflamapimod elected for inclusion in UK Experts-ALS Platform - marketscreener.com
CervoMed Inc. Announces Inclusion of Neflamapimod in EXPERTS-ALS Platform for ALS Trial - Quiver Quantitative
Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform - TradingView
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis - Yahoo Finance
Will CervoMed Inc. benefit from seasonalityJuly 2025 Setups & Smart Investment Allocation Tips - mfd.ru
Aug Summary: Is CervoMed Inc stock a good pick for beginnersWeekly Profit Recap & High Return Stock Watch Alerts - baoquankhu1.vn
Should You Buy CervoMed Inc (CRVO) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Form 4: Blackburn Kelly reports acquisition/exercise transactions in CRVO - Stock Titan
Is CervoMed Inc. stock a good pick for beginnersJuly 2025 Closing Moves & Growth Focused Stock Reports - mfd.ru
What’s the analyst consensus on CervoMed Inc.2025 Support & Resistance & High Accuracy Investment Signals - mfd.ru
CervoMed (NASDAQ:CRVO) Upgraded at Brookline Capital Management - Defense World
Winners Losers: Is ALCY affected by consumer sentiment2025 Macro Impact & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Market Outlook: Is CervoMed Inc currently under institutional pressure2025 Risk Factors & Fast Gain Swing Alerts - baoquankhu1.vn
Nasdaq Moves: Whats ACRES Commercial Realty Corps historical returnJuly 2025 Patterns & Smart Money Movement Tracker - baoquankhu1.vn
CervoMed Inc targets breakthrough in Lewy body dementia treatment - Traders Union
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Is CervoMed Inc stock good for income investorsWeekly Trade Summary & Daily Stock Trend Reports - baoquankhu1.vn
Geopolitics Watch: Is CervoMed Inc stock a good pick for beginnersTrade Volume Report & Verified Chart Pattern Signals - baoquankhu1.vn
Market Overview: Does Coupang Inc have pricing powerChart Signals & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Alpha Buying: Managing Biotech Risk With Insider Clues - Benzinga
CervoMed (NASDAQ:CRVO) Upgraded at Zacks Research - Defense World
Growth Review: Can VSTEW sustain its profitabilityTrade Exit Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Ideas Watch: Is CervoMed Inc DP8 stock overpriced at current multiplesTrade Analysis Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
Will CervoMed Inc. stock see insider buying2025 Breakouts & Breakdowns & Smart Swing Trading Techniques - Улправда
Will CervoMed Inc. stock deliver consistent dividends2025 Risk Factors & Fast Gain Swing Alerts - Улправда
Cervomed Inc (CRVO) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):